In cancer settings, SGLT-2i has been shown to inhibit glucose uptake, glycolysis, and AKT/mTOR signaling activation, while increasing AMPK expression in thyroid cancer cells, which resulted in decreased tumor cell proliferation and increased apoptosis [161]. The gene discussed is MTOR; the disease is cancer.